Balkan Journal of Medical Genetics

KDM3A, A NOVEL BLOOD-BASED BIOMARKER IN COLORECTAL CARCINOGENESIS
Polat D.1, Onur E.2,*, Yılmaz N.3, Sökücü M.4, Gerçeker O.F.1
*Corresponding Author: Assoc. Prof. Elif Onur, Department of Medical Biology, Faculty of Medicine, SANKO University, 27090 Gaziantep, Turkey; Phone:+90 342 211 6562; Fax: +90 342 211 6566; Email: elif.onur@sanko.edu.tr
page: 23

RESULTS

Characteristics of study subjects Of 50 CRC patients, 22 (44%) were women, and the mean age was 59.98±15.58. In all, 12.2% of patients were diagnosed as stage I, 28.6% were stage II, 20.4% were stage III, and 38.8% were stage IV. And the mean age of the control group was 52.82±12.1, and 35 of them (70%) were women. Analysis of HIF-1α, KDM3A and EMT marker gene expressions in CRC and control groups The gene expression levels comparing the groups were shown in table 2. HIF-1α, KDM3A, Slug, and ZEB-1 expression levels were detected as statistically significant between the CRC and the control groups. HIF-1α expression tended to increase among groups (median -1.32, and 4.25), and the difference was significant (p=0.0045) (Fig. 1A). The expression level of the KDM3A gene was significantly higher in the CRC group compared to the controls (p=0.0049) (Fig. 1B). Furthermore, the expression levels of the Slug and ZEB-1 mesenchymal marker genes was significantly higher in the CRC group compared to the controls (p=0.008 and p=0.029) (Fig. 1C-1D) There was no statistically significant difference between the groups in terms of E-cadherin and Claudin-1 gene expressions (p>0.05). The areas under the receiver operating characteristic (ROC) Curve (AUC), as well as the specificities and sensitivities for the optimal cut-points were computed to determine whether the KDM3A might be a prognostic factor in CRC. ROC analysis produced an AUC of 0.664 for separating CRC patients from controls by using the KDM3A expression level with 54% sensitivity and 85.4% specificity (Fig. 2). Gene expressions correlated with clinical features We next examined the HIF-1α, KDM3A, E-cadherin, Claudin-1, Slug, and ZEB-1 gene expression levels in different stages of CRC patients. No significant difference was observed between these subgroups (p>0.05).

Number 27 VOL. 27 (2), 2024	Number 27 VOL. 27 (1), 2024
Number 26 Number 26 VOL. 26(2), 2023 All in one	Number 26 VOL. 26(2), 2023
Number 26 VOL. 26, 2023 Supplement	Number 26 VOL. 26(1), 2023
Number 25 VOL. 25(2), 2022	Number 25 VOL. 25 (1), 2022
Number 24 VOL. 24(2), 2021	Number 24 VOL. 24(1), 2021
Number 23 VOL. 23(2), 2020	Number 22 VOL. 22(2), 2019
Number 22 VOL. 22(1), 2019	Number 22 VOL. 22, 2019 Supplement
Number 21 VOL. 21(2), 2018	Number 21 VOL. 21 (1), 2018
Number 21 VOL. 21, 2018 Supplement	Number 20 VOL. 20 (2), 2017
Number 20 VOL. 20 (1), 2017	Number 19 VOL. 19 (2), 2016
Number 19 VOL. 19 (1), 2016	Number 18 VOL. 18 (2), 2015
Number 18 VOL. 18 (1), 2015	Number 17 VOL. 17 (2), 2014
Number 17 VOL. 17 (1), 2014	Number 16 VOL. 16 (2), 2013
Number 16 VOL. 16 (1), 2013	Number 15 VOL. 15 (2), 2012
Number 15 VOL. 15, 2012 Supplement	Number 15 Vol. 15 (1), 2012
Number 14 14 - Vol. 14 (2), 2011	Number 14 The 9th Balkan Congress of Medical Genetics
Number 14 14 - Vol. 14 (1), 2011	Number 13 Vol. 13 (2), 2010
Number 13 Vol.13 (1), 2010	Number 12 Vol.12 (2), 2009
Number 12 Vol.12 (1), 2009	Number 11 Vol.11 (2),2008
Number 11 Vol.11 (1),2008	Number 10 Vol.10 (2), 2007
Number 10 10 (1),2007	Number 9 1&2, 2006
Number 9 3&4, 2006	Number 8 1&2, 2005
Number 8 3&4, 2004	Number 7 1&2, 2004
Number 6 3&4, 2003	Number 6 1&2, 2003
Number 5 3&4, 2002	Number 5 1&2, 2002
Number 4 Vol.3 (4), 2000	Number 4 Vol.2 (4), 1999
Number 4 Vol.1 (4), 1998	Number 4 3&4, 2001
Number 4 1&2, 2001	Number 3 Vol.3 (3), 2000
Number 3 Vol.2 (3), 1999	Number 3 Vol.1 (3), 1998
Number 2 Vol.3(2), 2000	Number 2 Vol.1 (2), 1998
Number 2 Vol.2 (2), 1999	Number 1 Vol.3 (1), 2000
Number 1 Vol.2 (1), 1999	Number 1 Vol.1 (1), 1998

About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact